This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Hepatic steatosis, also known as fatty liver disease, is a condition in which fat accumulates in the liver. In its mild form, it causes no symptoms and can be reversed with lifestyle modifications. However, if it progresses to its more severe form, it can lead to inflammation, cirrhosis, and even liver failure. The most common cause of hepatic steatosis is an unhealthy lifestyle. This includes a diet high in saturated fats and refined carbohydrates, excessive alcohol consumption, and physical inactivity. Other causes include certain medications, such as corticosteroids and methotrexate, and certain infectious agents, such as hepatitis C virus. The diagnosis of hepatic steatosis is usually made through imaging tests such as ultrasound, CT scan, or MRI. Blood tests can also provide information about liver function. Treatment of hepatic steatosis typically involves lifestyle modifications such as weight loss, increased physical activity, and a healthy diet low in saturated fats and refined carbohydrates. If the condition is caused by a medication, a doctor may recommend an alternative drug. In severe cases, medications such as statins may be used to reduce fat levels in the liver. In conclusion, hepatic steatosis is a common condition that can be reversed with lifestyle modifications. If it progresses to its more severe form, it can lead to serious complications and should be treated by a doctor.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States